Stem Cell Infusion Improves Walking Distance in Frail Older Adults in Phase IIb Trial
Start here
A double-blind, placebo-controlled Phase IIb dose-escalation trial (NCT03169231, N=148) tested a single intravenous infusion of mesenchymal stem cells in older frail adults. At nine months, the 200-million-cell dose group improved 6-minute walk distance by 63.4 meters more than placebo (p=0.0077), with dose- and time-dependent improvement across the study. Blood soluble TIE-2 levels declined with increasing dose, suggesting a possible marker of efficacy. The results support further development of cell therapy for age-related frailty; longer-term safety, confirmation in larger trials, and regulatory positioning remain open questions.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPickMesenchymal Stem Cell Randomized Trial Shows 63.4-Meter Greater 6-Minute Walk Improvement in Older Frail Adults Versus Placebo
A randomized Phase IIb trial showed that after a single intravenous infusion of mesenchymal stem cells, the 200-million-cell dose group improved 6-minute walk distance by 63.4 meters more than placebo at 9 months (p=0.0077). The double-blind, placebo-controlled dose-escalation study (NCT03169231, N=148) showed dose- and time-dependent improvement in walk distance. Blood soluble TIE-2 declined with dose, suggesting a potential efficacy marker.
Heat trend for this story
Heat now 9·Peak in the comparable set 10 (Oct 22 17:00)·Change over 24h in the comparable set +130%
The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's heat; the left and right arrow keys work too.